Skip to main content

Table 4 Adjusted risk ratio and 95% CI for medication effectiveness (algorithm result) (n = 16,305)

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Parameter

Adjusted risk ratio

95% CI

Drug therapy

 Non-TNF biologics ± DMARDs

Reference

 DMARDs

0.58

0.51–0.66

 TNFi ± DMARDs

0.94

0.86–1.03

 Tofacitinib ± DMARDs

0.75

0.42–1.34

Sex (female)

0.94

0.87–1.02

Age

1.01

1.00–1.01

Year of cohort entry

 2011

Reference

 2012

0.87

0.8–0.95

 2013

1.00

0.91–1.1

Oral glucocorticoid use 1 year prior to cohort entry

 No use

Reference

 Use of ≤ 7.5 mg/day of prednisone equivalent dose

0.94

0.88–1.02

 Use of > 7.5 mg/day of prednisone equivalent dose

1.07

0.90–1.26

Nonsteroidal anti-inflammatory drug use 1 year prior to cohort entry

0.94

0.88–1.01

Selective COX-2 inhibitors use 1 year prior to cohort entry

0.98

0.88–1.08

Charlson comorbidity index 1 year prior to cohort entry

0.91

0.86–0.95

Infection-related hospitalization 1 year prior to cohort entry

0.84

0.60–1.19

Number of emergency department visits 1 year prior to cohort entry

0.96

0.90–1.01

Number of physician visits 1 year prior to cohort entry

1.00

0.99–1.00

Number of rheumatology visits 1 year prior to cohort entry

1.00

1.00–1.01

Number of hospitalizations 1 year prior to cohort entry

0.97

0.89–1.06

  1. Abbreviations: DMARD Disease-modifying antirheumatic drug, TNFi Tumor necrosis factor inhibitors, COX-2 Cyclooxygenase-2